# A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Study · id `cardio:ct-nct07724340` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07724340](<https://clinicaltrials.gov/study/NCT07724340>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07724340

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07724340. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07724340, source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)
- Started: 2026-06-19 (actual) (ClinicalTrials.gov record NCT07724340, source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT07724340, source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07724340, source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07724340, source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07724340-2026-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
- Condition: Adults With Overweight/Obesity and Type 2 Diabetes
- Intervention (Drug): AT673 low dose
- Intervention (Drug): AT673 high dose
- Intervention (Drug): Placebo
- Lead sponsor: Antag Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: c3cba921307dbcb5dcf02a0e641bb3a7a345262c999ae8ca13dceecbdc0bcf90
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
